REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia

REVA Medical, LLC today announced primary endpoint results from the MOTIV BTK randomized pivotal clinical trial evaluating the MOTIV(r) sirolimus-eluting bioresorbable vascular scaffold in patients with critical limb-threatening ischemia (CLTI).